NasdaqGS - Nasdaq Real Time Price USD

Amneal Pharmaceuticals, Inc. (AMRX)

Compare
8.47 -0.11 (-1.28%)
At close: October 21 at 4:00 PM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
2,597,992.00
2,393,607.00
2,212,304.00
2,093,669.00
1,992,523.00
--
Cost of Revenue
1,687,627.00
1,573,042.00
1,427,596.00
1,324,696.00
1,364,130.00
--
Gross Profit
910,365.00
820,565.00
784,708.00
768,973.00
628,393.00
--
Operating Expense
631,503.00
596,315.00
595,786.00
575,067.00
517,312.00
--
Operating Income
278,862.00
224,250.00
188,922.00
193,906.00
111,081.00
--
Net Non Operating Interest Income Expense
-282,684.00
-251,434.00
-158,668.00
-136,325.00
-145,998.00
--
Other Income Expense
-111,799.00
-13,086.00
-278,381.00
-26,215.00
-863.00
--
Pretax Income
-115,621.00
-40,270.00
-248,127.00
31,366.00
-35,780.00
--
Tax Provision
17,581.00
8,452.00
6,662.00
11,196.00
-104,358.00
--
Net Income Common Stockholders
-174,616.00
-83,993.00
-129,986.00
10,624.00
91,059.00
--
Diluted NI Available to Com Stockholders
-174,616.00
-83,993.00
-129,986.00
10,624.00
91,059.00
--
Basic EPS
-0.79
-0.48
-0.86
0.07
0.62
--
Diluted EPS
-0.79
-0.48
-0.86
0.07
0.61
--
Basic Average Shares
253,771.00
176,136.00
150,944.00
148,922.00
147,443.00
--
Diluted Average Shares
253,771.00
176,136.00
150,944.00
151,821.00
148,913.00
--
Total Operating Income as Reported
174,565.00
204,374.00
-94,928.00
152,716.00
91,155.00
--
Total Expenses
2,319,130.00
2,169,357.00
2,023,382.00
1,899,763.00
1,881,442.00
--
Net Income from Continuing & Discontinued Operation
-174,616.00
-83,993.00
-129,986.00
10,624.00
91,059.00
--
Normalized Income
-79,367.28
-69,611.05
104,023.06
37,337.44
93,579.69
--
Interest Expense
241,879.00
210,629.00
158,377.00
136,325.00
145,998.00
--
Net Interest Income
-282,684.00
-251,434.00
-158,668.00
-136,325.00
-145,998.00
--
EBIT
126,258.00
170,359.00
-89,750.00
167,691.00
110,218.00
--
EBITDA
351,497.00
399,759.00
150,425.00
401,097.00
345,605.00
--
Reconciled Cost of Revenue
1,687,627.00
1,573,042.00
1,427,596.00
1,324,696.00
1,364,130.00
--
Reconciled Depreciation
225,239.00
229,400.00
240,175.00
233,406.00
235,387.00
--
Net Income from Continuing Operation Net Minority Interest
-174,616.00
-83,993.00
-129,986.00
10,624.00
91,059.00
--
Total Unusual Items Excluding Goodwill
-120,568.00
-18,205.00
-296,214.00
-41,545.00
-3,453.00
--
Total Unusual Items
-120,568.00
-18,205.00
-296,214.00
-41,545.00
-3,453.00
--
Normalized EBITDA
472,065.00
417,964.00
446,639.00
442,642.00
349,058.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-25,319.28
-3,823.05
-62,204.94
-14,831.57
-932.31
--
12/31/2019 - 5/7/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers